Nebenwirkungen · Qarziba (previously Dinutuximab beta EUSA and Dinutuximab beta Apeiron)
Qarziba 4.5 mg/mL concentrate for solution for infusion · Abschnitt 4.8 · PDF-Seite 9–10
HOS-132932 · Präparat HOS-097326
9 System organ Very common Common Uncommon Not known class General disorders pyrexia, chills, injection site reaction and pain*, peripheral administration oedema, face site conditions oedema Investigations increased weight, decreased weight, increased decreased glomerular transaminases, filtration rate, increased gamma hypertriglyceridaemia, glutamyltransferase, prolonged activated increased blood partial thromboplastin bilirubin increased time, prolonged blood creatinine prothrombin time, prolonged thrombin time *includes abdominal pain, pain in extremity, oropharyngeal pain, and Back pain reported in >10% of patients. In addition, other common pain types reported were arthralgia, injection site pain, musculoskeletal pain, bone pain, chest pain, and neck pain.
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2025-11-26T12:03:00Z · SHA-256 a4bdc364f40b9b2e912945f81bd2f4f640ba5c63c638062755ae747372a4350a · Passage abfb007ef1d00820dd222369c3833aa4136ec51bb16faba2d113a3cd3cb0e423 · Zeichen 5892–7069 im Abschnitt